PCSK9 and metabolic syndrome: The latest European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) 2019 guidelines for dyslipidemia management with revised LDL-C treatment goals (< 55 mg/dL for patients at very high risk) made their achievement with conventional LLT using statins and/or ezetimibe even more difficult [73], implicating that many patients would need more potent lipid-lowering drugs such as PCSK9 inhibitors to achieve these goals.